IFN-alpha 1/IFNA1 蛋白, Mouse (P.pastoris, His)

IFN-alpha 1 (IFNA1), belongs to type I interferon family, is produced by macrophages with antiviral activities^[1]. IFN-alpha 1 involves in the activation of JAK1 and TYK2 pathway^[4], exerts function by inhibiting viral replication as well as modulating immune response^[3]. IFN-alpha 1/IFNA1 Protein, Mouse (P.pastoris, His) is produced in P.pastoris yeast cells with a C-Terminal His-tag.

IFN-α 1（IFNA1；IFN-α1）属于 α/β 干扰素家族，由巨噬细胞产生，具有抗病毒活性^[1]。干扰素（IFN）最初被认为是一种在体外“干扰”病毒复制的物质。IFN-α/β及相关分子被归类为I型干扰素，其他两类分别为II型干扰素（IFN-γ）和III型干扰素（IFN-λ）^[2]。
IFN 与三种类型特异性受体之一结合，从而激活 JAK1 和 TYK2^[3]。这种信号转导导致 STAT1 和 STAT2 磷酸化，并最终与 IFN 调节因子 9 (IRF9) 相关并形成 IFN 刺激的基因因子 3 (ISGF3) 复合物。因此，ISGF3 复合物诱导 IFN 刺激基因 (ISG) 的转录，随后对先天性和适应性免疫反应产生免疫调节作用^[4]。
I 型 IFN 与免疫系统的相互作用系统通过其对树突状细胞 (DC) 的影响，对于产生持久的抗肿瘤反应非常重要^[5]。IFN已广泛用于动物疾病模型，小鼠IFNA1蛋白氨基酸序列与人类有很大差异（62.96%）。

Measured in antiviral assays using L929 cells infected with vesicular stomatitisvirus (VSV) and the ED₅₀ is 20-100 pg/mL.

Mouse

P. pastoris

C-His

P01572 (C24-K189)

15962  [NCBI]

Approximately 20.5 kDa

Greater than 90% as determined by reducing SDS-PAGE.

溶液.

Supplied as a 0.22 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

N/A.

Stored at -80°C for 1 year. It is stable at -20°C for 3 months after opening. It is recommended to freeze aliquots at -80°C for extended storage. Avoid repeated freeze-thaw cycles.

Shipping with dry ice.

• [1]. Zoon KC, et al. Purification and characterization of multiple components of human lymphoblastoid interferon-alpha. J Biol Chem. 1992 Jul 25;267(21):15210-6.  [Content Brief]

  [2]. Zhang SY, et al. Inborn errors of interferon (IFN)-mediated immunity in humans: insights into the respective roles of IFN-alpha/beta, IFN-gamma, and IFN-lambda in host defense. Immunol Rev. 2008 Dec;226:29-40.  [Content Brief]

  [3]. Gibbert K, et al. IFN-α subtypes: distinct biological activities in anti-viral therapy. Br J Pharmacol. 2013 Mar;168(5):1048-58.  [Content Brief]

  [4]. De Ceuninck F, et al. IFN-α: A key therapeutic target for multiple autoimmune rheumatic diseases. Drug Discov Today. 2021 Oct;26(10):2465-2473.  [Content Brief]

  [5]. Lapenta C, et al. IFN-Alpha-Mediated Differentiation of Dendritic Cells for Cancer Immunotherapy: Advances and Perspectives. Vaccines (Basel). 2020 Oct 19;8(4):617.  [Content Brief]